You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Baxter
Moodys
Merck
Boehringer Ingelheim

Last Updated: June 5, 2020

DrugPatentWatch Database Preview

ZETONNA Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which patents cover Zetonna, and what generic alternatives are available?

Zetonna is a drug marketed by Covis Pharma Bv and is included in one NDA. There is one patent protecting this drug.

This drug has fourteen patent family members in twelve countries.

The generic ingredient in ZETONNA is ciclesonide. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ciclesonide profile page.

US ANDA Litigation and Generic Entry Outlook for Zetonna

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Drug patent expirations by year for ZETONNA
Drug Prices for ZETONNA

See drug prices for ZETONNA

Recent Clinical Trials for ZETONNA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
SunovionPhase 4

See all ZETONNA clinical trials

Recent Litigation for ZETONNA

Identify potential future generic entrants

District Court Litigation
Case NameDate
ORTHO-MCNEIL PHARMACEUTICAL, INC. v. LUPIN PHARMACEUTICALS, INC.2006-10-17

See all ZETONNA litigation

Synonyms for ZETONNA
(11?,16?)-16,17-[[(R)-Cyclohexylmethylene]bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)-pregna-1,4-diene-3,20-dione
(11?,16?)-16,17-[[(R)-Cyclohexylmethylene]bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)pregna-1,4-diene-3,20-dione
(R)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate
126544-47-6
141845-82-1
2-((6aR,6bS,7S,8aS,8bS,10R,11aR,12aS,12bS)-10-cyclohexyl-7-hydroxy-6a,8a-dimethyl-4-oxo-1,2,4,6a,6b,7,8,8a,11a,12,12a,12b-dodecahydro-8bH-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-8b-yl)-
2-oxoethyl isobutyrate
2H-Naphth (2',1':4,5) indeno (1,2-d) (1,3) dioxole, pregna-1,4-diene-3,20-dione deriv.
544C476
AC-1330
AC1MIWNR
AKOS015994702
Alvesco
Alvesco (TN)
Alvesco 160
Alvesco 80
Alvesco HFA
Alvesco, Ciclesonide
B-9207-015
BDBM50247997
BI54903
BTR-15
BTR-15K
BY-9010
BYK-20426
C-23151
CAS-141845-82-1
CC-25775
CHEBI:31397
CHEMBL2040682
Ciclesonide
Ciclesonide (JAN/USAN/INN)
Ciclesonide [INN]
Ciclesonide [USAN:INN]
Ciclesonide, >=98% (HPLC)
Ciclesonide, European Pharmacopoeia (EP) Reference Standard
CS-2867
D01703
DB01410
DSSTox_CID_26659
DSSTox_GSID_46659
DSSTox_RID_81802
DTXSID9046659
el-87-6
GTPL7469
HMS3714N07
HY-B0625
KS-1165
LS-186047
LUKZNWIVRBCLON-GXOBDPJESA-N
NCGC00167484-01
NCGC00167972-01
O945
Omnair
Omnaris
Omnaris (TN)
Omnaris HFA
Osonase
Osonide
Pregna-1,4-diene-3,20-dione, 16,17-(((R)-cyclohexylmethylene)bis(oxy))-11-hydroxy-21-(2-methyl-1-oxopropoxy)-, (11beta,16alpha)-
Pregna-1,4-diene-3,20-dione, 16,17-((cyclohexylmethylene)bis(oxy))-11-hydroxy-21-(2-methyl-1-oxopropoxy)-, (11beta,16alpha(R))-
Q5119448
RPR 251526
RPR-251526
RPR251526
s4646
S59502J185
SCHEMBL3688
SR-01000942227
SR-01000942227-1
TBN-15
Tox21_112486
UNII-S59502J185
ZINC3915154

US Patents and Regulatory Information for ZETONNA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Covis Pharma Bv ZETONNA ciclesonide AEROSOL, METERED;NASAL 202129-001 Jan 20, 2012 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ZETONNA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Covis Pharma Bv ZETONNA ciclesonide AEROSOL, METERED;NASAL 202129-001 Jan 20, 2012   Start Trial   Start Trial
Covis Pharma Bv ZETONNA ciclesonide AEROSOL, METERED;NASAL 202129-001 Jan 20, 2012   Start Trial   Start Trial
Covis Pharma Bv ZETONNA ciclesonide AEROSOL, METERED;NASAL 202129-001 Jan 20, 2012   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for ZETONNA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0983058 PA2005006,C0983058 Lithuania   Start Trial PRODUCT NAME: CICLESONIDUM (11BETA,16ALFA)-16,17-(((R)-CIKLOHEKSILMETILEN)BIS(OKSI))-11-HIDROKSI-21-(2-METIL-1OKSOPROPOKSI)PREGNA-1,4-DIEN-3,20-DIONAS; REGISTRATION NO/DATE: LT/1/05/0181/001, LT/1/05/0181/002, LT/1/05/0181/003 20050321
0983058 CA 2005 00036 Denmark   Start Trial
0983058 SPC022/2005 Ireland   Start Trial SPC022/2005, 20060612, EXPIRES: 20190415
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Baxter
Moodys
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.